Alterity Data Shows Promise for MSA Treatment, Bolsters Phase 3 Plans
Event summary
- Alterity Therapeutics presented new data from the ATH434-201 Phase 2 trial at the American Academy of Neurology (AAN) meeting on April 22, 2026.
- The data demonstrated a reduction in functional decline using the newly developed MSA Combined Outcome Assessment (MuSyCA) scale, with a treatment effect ranging from -1.9 to -4.0 points at Week 52.
- ATH434 also showed a slowing of disease progression on the modified UMSARS I scale, with relative treatment effects of 35% and 53% at different doses.
- MuSyCA integrates patient-reported function with clinical assessment and is intended to improve detection of disease progression in clinical trials.
The big picture
The development of the MuSyCA scale represents a significant advancement in assessing disease progression in MSA, a rare and underserved neurodegenerative disorder. Alterity's data, if consistently replicated in Phase 3, could establish ATH434 as the first disease-modifying therapy for MSA, a market with limited treatment options and a significant unmet need. The company's progress is being watched closely as it prepares to initiate a pivotal Phase 3 trial, a critical step toward commercialization and potential revenue generation.
What we're watching
- Regulatory Pathway
- The FDA’s Fast Track and Orphan Drug designations suggest accelerated review, but the efficacy data will be scrutinized closely during Phase 3 engagement, particularly given the novelty of the MuSyCA scale.
- MuSyCA Adoption
- Wider adoption of the MuSyCA scale by other researchers and pharmaceutical companies will be crucial for validating its utility and establishing a consistent benchmark for MSA clinical trials.
- Phase 3 Execution
- The success of Alterity's planned Phase 3 trial hinges on patient recruitment and retention, given the rarity of MSA and the progressive nature of the disease.
Related topics